Liraglutide Treatment in Obese Infertile PCOS Women

Exclusion Criteria

• •Diabetic ketoacidosis or other acute complications of diabetes;
• •HbA1c ≥ 9.0% before enrollment;
• •Using drugs that affect appetite or nutrient absorption within the past 2 months (metformin excluded);
• •Uncontrolled hyperthyroidism or hypothyroidism, hypertension, systemic autoimmune diseases, etc. that may affect pregnancy and fetal development;
• •17 hydroxyprogesterone in follicualr phase \> 2.0 ng/ml;
• •Serious cardiovascular, digestive, liver, or kidney diseases, HBsAg-positive chronic hepatitis B, active pulmonary tuberculosis, or AIDS, etc. that are infectious or hereditary diseases;
• •Any psychiatric or psychological disorders requiring drug treatment;
• •Poor pregnancy and delivery history: recurrent failed implantations ≥3 times, spontaneous abortions ≥2 times; history of stillbirth, dystocia, or birth defects; previous pregnancies with preeclampsia, eclampsia, or HELLP syndrome;
• •Uncontrolled metabolic, autoimmune, or hereditary disease in the husband;
• •A contraindication or relative contraindication to using GLP-1 receptor agonists (history of medullary thyroid carcinoma or family history of medullary thyroid carcinoma, acute cholecystitis or pancreatitis in the acute phase or history of previous attacks, GLP-1 receptor agonist allergy, etc.);
• •Failure to comply with the contraceptive requirements of the study design;
• •Failure to take medication regularly and follow up;
• •Current smokers, drug addicts, alcoholics, or individuals with substance abuse;
• •Participants who have participated in any clinical trial within the past 3 months prior to screening;
• •Individuals with other conditions deemed unsuitable for participation in this clinical trial by the investigator;